Close Menu

NEW YORK (GenomeWeb) – MDx startup Twistnostics has renamed itself Scanogen and shifted its business status as it works to develop its first commercial product based on its proprietary molecular detection platform.

Scanogen CEO Alfredo Celedon told GenomeWeb this week that important technological advancements over the last year have brought the firm to the point where it is now seeking investment and partnerships to advance the product, a tuberculosis diagnostic.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.